AstraZeneca Reports Phase 2 Data for Lebrikizumab in Dermatomyositis

AstraZeneca today announced Phase 2 results for Lebrikizumab in patients with Dermatomyositis. The study demonstrated that Lebrikizumab reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Dermatomyositis and support the continued development of Lebrikizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Lebrikizumab was consistent with previous observations, with no new safety signals identified.